4
Shared Docs
4
Same-Page
4 / 4
Mentions
iant pharmacy benefits manager.“If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug class,” Brennan says. Praluent, an injection, lowers low-density lipoprotein, the so-called “bad cholesterol”, by as much as 60%, far more than the statin drugs alo
Page: HOUSE_OVERSIGHT_025889 →man of cardiology at the Cleveland Clinic. “It’s very promising.” But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits manager.“If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug c
Page: HOUSE_OVERSIGHT_025889 →iant pharmacy benefits manager.“If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug class,” Brennan says. Praluent, an injection, lowers low-density lipoprotein, the so-called “bad cholesterol”, by as much as 60%, far more than the statin drugs alo
Page: HOUSE_OVERSIGHT_026363 →man of cardiology at the Cleveland Clinic. “It’s very promising.” But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits manager.“If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug c
Page: HOUSE_OVERSIGHT_026363 →he world's most urgent challenges. Here, Troyen Brennan of CVS Caremark, Institute Chairman Mike Milken,
00 attendees who challenged one another to spark change and find solutions to some of the world's most urgent challenges. Here, Troyen Brennan of CVS Caremark, Institute Chairman Mike Milken, Tom Frieden of the Centers for Disease Control and Lynn Goldman of George Washington University share a light mo
nt pharmacy benefits manager."If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug class," Brennan says. Praluent, an injection, lowers low-density lipoprotein, the so-called "bad cholesterol", by as much as 60%, far more than the statin drugs al
man of cardiology at the Cleveland Clinic. "It's very promising." But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits manager."If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug
Entities connected to both John Brennan and CVS Caremark

Jeffrey Epstein
PERSON
Donald Trump
PERSON
Pfizer
ORGANIZATION
the Food and Drug Administration
ORGANIZATION
Amgen
ORGANIZATIONRegeneron
PERSONTarrytown
LOCATION
Troy Brennan
PERSON
the Cleveland Clinic
ORGANIZATION
Mark Schoenebaum
PERSON
Geoffrey Porges
PERSON
Sanford C. Bernstein
ORGANIZATIONSchleifer
PERSON
Olivier Brandicourt
PERSON
Matthew Herper
PERSONPraluent
ORGANIZATIONNissen
PERSONLeonard S. Schleifer
PERSONthe Human Genome
ORGANIZATIONSultan Bin Sulayern
PERSON